CCR 16 1217 - LR

1 Cancer Therapy: Preclinical Clinical
Cancer
Research
2
3 Q1 Multifaceted Role of BTLA in the Control of CD8
4 Q2 T-cell Fate after Antigen Encounter
5 AU Krit Ritthipichai1,2, Cara L. Haymaker1, Melisa Martinez3, Andrew Aschenbrenner4,
6 Xiaohui Yi5, Minying Zhang1, Charuta Kale1, Luis M. Vence5, Jason Roszik1,
7 Yared Hailemichael1, Willem W. Overwijk1, Navin Varadarajan3, Roza Nurieva2,6,
8 Laszlo G. Radvanyi1, Patrick Hwu1,2, and Chantale Bernatchez1,2
9 Abstract
10 Purpose: Adoptive T-cell therapy using autologous tumor- immunodecient NOD-scid IL2Rgammanull (NSG) tumor-bear- 26
11 inltrating lymphocytes (TIL) has shown an overall clinical ing mice treated with autologous TILs. 27
12 response rate 40%50% in metastatic melanoma patients. BTLA Results: CD8BTLA TILs could not control tumor growth in 28
13 (B-and-T lymphocyte attenuator) expression on transferred CD8 vivo as well as their BTLA counterpart and antigen-specic 29
14 TILs was associated with better clinical outcome. The suppressive CD8BTLA T cells had impaired recall response to a vaccine. 30
15 function of the ITIM and ITSM motifs of BTLA is well described. However, CD8BTLA TILs displayed improved survival follow- 31
16 Here, we sought to determine the functional characteristics of the ing the killing of a tumor target and heightened "serial killing" 32
17 CD8BTLATIL subset and dene the contribution of the Grb2 capacity. Using mutants of BTLA signaling motifs, we uncovered a 33
18 motif of BTLA in T-cell costimulation. costimulatory function mediated by Grb2 through enhancing the 34
19 Experimental Design: We determined the functional role and secretion of IL2 and the activation of Src after TCR stimulation. 35
20 downstream signal of BTLA in both human CD8 TILs and mouse Conclusions: Our data portrays BTLA as a molecule with the 36
21 CD8 T cells. Functional assays were used including single-cell singular ability to provide both costimulatory and coinhibitory 37
22 analysis, reverse-phase protein array (RPPA), antigen-specic signals to activated CD8 T cells, resulting in extended survival, 38
23 vaccination models with adoptively transferred TCR-transgenic improved tumor control, and the development of a functional 39
24 T cells as well as patient-derived xenograft (PDX) model using recall response. Clin Cancer Res; 116. 2017 AACR. 40
41
42 Introduction unexpected nding that a population of CD8 TILs expressing a 50

molecule known to attenuate T-cell response, the B and T lym- 51
43 Adoptive T-cell therapy (ACT) using the body's own expanded
phocyte attenuator (BTLA), was strongly associated with a positive 52
44 tumor-inltrating lymphocytes (TIL) with prior lymphodepletion
clinical response (4). 53
45 and followed by high-dose IL2 administration has demonstrated
BTLA is an inhibitory molecule expressed by T cells, B cells, 54
46 an overall response rate of 38%51% in multiple clinical trials for
dendritic cells, and NK cells (5). Herpes virus entry mediator 55
47 stage IIIC/IV metastatic melanoma (14). A comprehensive
(HVEM), a TNF receptor superfamily member 14 (TNFRSF14), is 56
48 immunophenotyping of TIL infusion products has revealed an
the known ligand for BTLA (6). The cytoplasmic domain of BTLA 57
consists of three motifs; an immunoreceptor tyrosine-based inhi- 58
bition motif (ITIM), an immunoreceptor tyrosine-based switch 59
1
Department of Melanoma Medical Oncology, The University of Texas MD motif (ITSM), and a growth factor receptorbound protein 2 60
Anderson Cancer Center, Houston, Texas. 2Graduate Program in Immunology, motif (Grb2). Ligation of BTLA by HVEM has been shown to 61
Graduate School of Biomedical Sciences, The University of Texas Health Science recruit Src homology 2 (SH2) domain-containing phosphatase 1 62
Center at Houston, Houston, Texas. 3Department of Chemical and Biomolecular
Engineering, Cullen College of Engineering, University of Houston, Texas.
and 2 (SHP-1 and SHP-2) to the ITIM and ITSM motifs, resulting 63
4
Graduate Program in Biostatistics, School of Public Health, The University of in suppression of T-cell receptor (TCR) activation (5, 7). Indeed, 64
Texas Health Science Center at Houston, Houston, Texas. 5Immunology Plat- ITIM and ITSM motifs were required for the full function of BTLA 65
form, Department of Immunology, The University of Texas MD Anderson Cancer to inhibit T-cell proliferation and cytokine production including 66
Center, Houston, Texas. 6Department of Immunology, The University of Texas IFNg, IL2, and IL10 (8, 9). A recent report indicated that PD-1 67
Q3 MD Anderson Cancer Center, Houston, Texas. ligation, which also contains ITIM and ITSM motifs, selectively 68
Note: Supplementary data for this article are available at Clinical Cancer inhibits both the Akt and RasMEKERK pathways (10). So far, it 69
Research Online (http://clincancerres.aacrjournals.org/). remains inconclusive whether BTLA utilizes mechanism similar to 70
Current address for L.G. Radvanyi: Global Immuno-Oncology Research, EMD PD-1 as ITIM and ITSM motifs are commonly shared between 71
Serono Research Institute, Billerica, MA. these two receptors. 72
Corresponding Author: Chantale Bernatchez, The University of Texas M.D. Unlike PD-1, BTLA also harbors a Grb2 motif. Although the 73
Q4 Anderson Cancer Center, 7455 Fannin St., Houston, TX 77054. Phone: 713- function of the Grb2 motif remains unclear, some evidence 74
563-8830; Fax: 713-745-0134; E-mail: cbernatchez@mdanderson.org suggests that it may actually transmit a positive signal. In fact, 75
doi: 10.1158/1078-0432.CCR-16-1217 an in vitro binding assay demonstrated the potential interaction of 76
2017 American Association for Cancer Research. the Grb2-binding motif with the Grb2 adaptor protein and the 77
www.aacrjournals.org 1
Ritthipichai et al.
Translational Relevance Materials and Methods 120

Cell lines 121
BTLA (B-and-T lymphocyte attenuator) is a negative T-cell
Platinum-E retroviral packaging cell line, MEL 526 tumor line, 122
cosignaling molecule. Its expression on CD8 tumor-inltrat-
and primary melanoma tumor cell line #2549, as well as B16F10, 123
ing lymphocytes (TIL) unexpectedly associated with better
and B16OVA were maintained in Roswell Park Memorial Institute 124
clinical outcome in metastatic melanoma patients treated with
(RPMI) medium supplemented with 10% FBS (Gemini bio 125
adoptive T-cell therapy using TILs. We sought to determine
product), 10 mmol/L HEPES (Gibco), 10 mmol/L penicillin 126
whether BTLA signaling could positively impact T cells. Our
streptomycin (Gibco), and 10 mmol/L Glutamine (Gibco), sele- 127
results demonstrate that the CD8BTLA TIL subset has a
niumtransferrininsulin (Gibco), and 0.05 mmol/L b-mercap- 128
survival advantage following the killing of a tumor target in
toethanol (Gibco) as described previously (2, 19). Platinum-E 129
comparison with its BTLA counterpart, which may explain
retro packing cell line was purchased from Cell Biolabs. MEL 526 130
the superior in vivo persistence of this subset after TIL infusion.
tumor line was obtained from Dr. Steven A. Rosenberg at the 131
Interestingly, the Grb2 motif of BTLA was found to promote
National Cancer Institute. Autologous primary melanoma tumor 132
IL2 production following BTLA engagement in the context of a
cell line #2549 was generated at MD Anderson Cancer Center 133
TCR stimulation, and the presence of BTLA on CD8 T cells
(Houston, TX) from a tumor sample of a patient enrolled on an 134
was required to develop a robust recall response. Therefore,
ongoing adoptive T-cell therapy study. The cell line #2549 was last 135
developing a strategy to selectively expand and infuse
authenticated on 03/24/2015 by STR DNA ngerprinting using 136
CD8BTLA TILs may enhance TIL persistence postinfusion
the Promega 16 High Sensitivity STR Kit (Catalog #DC2100). The 137
and result in superior clinical outcome.
STR proles were compared to online search databases (DSMZ/ 138
ATCC/JCRB/RIKEN) of 2,455 known proles; along with the MD 139
Anderson Characterized Cell Line Core (CCLC) database of 2,556 140
80 p85 subunit of phosphatidylinositol 3-kinase (p85 PI3K; refs. 7, known proles. The STR proles matched known DNA ngerprint 141
81 11). Interestingly, a gene expression analysis of mouse CD4 T of patient's PBMCs. No authentication was performed in all other 142
82 cells following activation by anti-CD3 and anti-BTLA demonstrat- cell lines. 143
83 ed a highly overlapping transcription prole with that produced
84 by anti-CD3 in combination with positive costimulators (CD28, Patient tumor sample acquisition 144
85 ICOS, and CD80), but not with inhibitory molecules (PD-1 and Tumor samples were obtained from patients with stage IIIc and 145
86 CTLA-4; ref. 12). stage IV melanoma undergoing surgery at The University of Texas 146
87 Emerging evidence also demonstrates that BTLA serves as a T- MD Anderson Cancer Center according to an Institutional Review 147
88 cell differentiation marker in human T cells as BTLA expression is Boardapproved protocol and with patient consent (IRB# 2004- 148
89 highly enriched in nave T cells and central memory T cells (Tcm) 0069, LAB06-0755, NCT00338377). This study was carried out in 149
90 and downregulated upon T-cell differentiation (13). Our recent compliance with the protocol and Good Clinical Practice con- 150
91 work demonstrated that CD8BTLATILs exhibited the molecular cerning medical research in humans, as described in the Decla- 151
92 signature of less-differentiated T cells as compared with their ration of Helsinki. 152
93 CD8BTLA counterpart and had increased persistence following
94 adoptive transfer in treated patients (14). Several studies in both Generation of TILs 153
95 immunodecient murine and non-human primate models also Fragments from melanoma tumors were cut into 1 to 2 mm3. 154
96 demonstrated that central memoryderived effector CD8 T cells Each fragment was placed into a single wells in 24-well culture 155
97 established a pool of in vivo persistent memory T cells (1518). In plates (Falcon) and maintained with RPMI supplemented with 156
98 addition, adoptive transfer of memory T cells with stem cell 10% heat-inactivated Human AB serum (Gemini bio product), 157
99 properties (TSCM) was shown to confer in vivo persistence and IL2 6,000 IU/mL (Proleukin, Novartis), 10 mmol/L HEPES, 158
100 better tumor control due to enhanced survival and antitumor 10 mmol/L penicillinstreptomycin (Gibco), and 10 mmol/L 159
101 properties (15). Glutamine (Gibco) as described previously (20). 160
102 Thus far, it remains understudied whether the intrinsic prop-
103 erties of less-differentiated TILs highly enriched in BTLA-expres- Retroviral constructs of BTLA wild-type and mutants 161
104 sing cells and/or BTLA signaling itself contribute to the favorable Murine BTLA was amplied from fully sequenced murine BTLA 162
105 clinical outcome of TIL-treated patients. In this study, we have from Mammalian Gene Collection Clones (MGC, Open Biosys- 163
106 uncovered survival advantages of the BTLA subset that allows for tems) by PCR with primers mBTLA-F and R (Supplementary 164
107 serial killing of target tumor cells, which may explain our previous Table S1). The PCR products were cloned into pRVKM retroviral 165
108 correlation between this subset and response to TIL ACT. In vectors. To generate BTLA mutants, we substituted tyrosine for 166
109 addition, our results unveiled a role for the BTLA-associated phenyl alanine in either Grb2 motifs or ITIM and ITSM motifs of 167
110 Grb2-binding motif in T-cell proliferation and IL2 production BTLA cytoplasmic tails (Supplementary Table S2). These included 168
111 following TCR engagement that was independent of the inhibi- murine DGrb2 mutants (Y245F), and murine D ITIM and ITSM 169
112 tory function of ITIM/ITSM motifs. The use of a pmel BTLA mutants (Y274F and Y299F). Sequences of all constructs were 170
113 knockout system demonstrates a weaker priming of T cells in validated by DNA sequencing. 171
114 response to the cognate antigen and the absence of a recall
115 response. Overall, this study has uncovered a previously unap- Retroviral transduction of mouse BTLA-KO-T cells 172
116 preciated role of the Grb2 motif of BTLA in providing positive pRVKM retroviral vectors and pEco plasmids were cotrans- 173
117 costimulatory signal to T cells and the ability of CD8BTLATIL to fected into Plate-E cells using using PolyJet (Signagen Laborato- 174
118 function as serial killers. ries). The supernatants were harvested 60 hours later and 175
2 Clin Cancer Res; 2017 Clinical Cancer Research

BTLA Promotes CD8 T-cell Survival
178 concentrated using Vivaspin-20 (Vivaproducts). Splenocytes from (according to manufacturer's protocol; BD Pharmingen), then 235
179 OT-1 BTLA KO mice were cultured with RPMI1640 with 10% FBS stained with anti-cleaved caspase-3 (clone CPP32; BD Phar- 236
180 and hIL2 at 300 IU/mL, and activated with anti-mouse CD3 at a mingen), and analyzed by a BD FACSCanto II (BD Biosciences). 237
181 concentration of 0.3 mg/mL (Clone 145-2C11, eBioscience) for
182 24 hours. The cells were then infected with a concentrated retro- Cell proliferation assay 238
183 virus and further expanded in RPMI1640 with 10% FBS and hIL2 Murine OT-1 BTLA KO expressing BTLA WT or mutants were 239
184 for 3 days. The cells were sorted on the basis of the expression of labeled with eFluor670 and restimulated with dendritic cells 240
185 GFP using a FACSAria (BD Biosciences) and propagated with hIL2 alone or dendritic cells pulsed with OVA peptide (SIINFEKL; 241
186 at 300 IU/mL for 5 days. American peptide) at a ratio of 1:40 for 48 hours prior to being 242
analyzed using a BD FACSCanto II (BD Biosciences). 243
187 Reverse-phase protein array
188 Murine OT-1 BTLA KO cells overexpressing BTLA WT or Nanowell arraybased cytolytic assay 244
189 mutants constructs were restimulated with either 10 ng/mL TILs and tumor cells were labeled with 1 mmol/L of red 245
190 anti-mouse CD3 (Clone 145-2C11, BD Pharmingen) alone or uorescence dye (PKH26, Sigma) and 1 mL of green uorescence 246
191 with recombinant mouse HVEM Fc (R&D Systems) plate-bound dye (PKH68, Sigma), respectively. The cells were loaded onto 247
192 for 8 hours prior to harvest with the cell lysis buffer (kindly nanowells at concentration of 1 106/mL. Target cell cytolysis 248
193 provided by RPPA core facility at The University of Texas MD mediated by TILs was monitored using a Carl Zeiss Axio 249
194 Anderson Cancer Center). The cell lysates were centrifuged at Observer tted with Hamamatsu EM-CCD camera using 10 250
195 14,000 rpm for 10 minutes at 4 C. The protein supernatant was 0.3 NA objective. Apoptotic cells became green when stained 251
196 quantied using protein assay kit (Thermo Scientic). Reverse- with Annexin V conjugated with Alexa 647 as described 252
197 phase protein array (RPPA) was processed and normalized as previously (23). 253
198 described previously (21). Differential fold expression of protein
199 was analyzed using Linear models and empirical Bayes methods In vivo killing of melanoma tumors using an NSG ACT model 254
200 (22). Volcano plots were generated using R system. For human NOD-scid IL2Rgammanull (NSG) mice were engrafted with 255
201 TILs, four TIL lines were stained with anti-CD8 (clone RPA-T8, BD either 5 106 MEL 526 MEL tumor cells or 5 106 autologous 256
202 Pharmingen), anti-BTLA (clone J168, BD Pharmingen), and Sytox primary melanoma tumor cells. On day 12, either 1 107 sorted 257
203 blue (Molecular Probe) under aseptic condition. The cells were CD8BTLA or sorted CD8BTLA were adoptively transferred 258
204 sorted on the basis of expression of CD8BTLA using FACSAria into tumor-bearing mice (n 58 per group). Recombinant 259
205 (BD Biosciences). On the next day, sorted TILs were restimulated human IL2 (Proleukin, Prometheus) was administered intraper- 260
206 with anti-human CD3 (clone OKT-3, eBioscience) with or with- itoneally at a concentration of 6 105 IU immediately after the 261
207 out recombinant human HVEM-Fc (R&D Systems) plate-bound TIL transfer and daily for three days. Tumor size was measured 262
208 for 8 hours prior to harvest with the cell lysis buffer. The protein every other day. Mice were sacriced when tumors exceeded 263
209 samples were processed, normalized, and analyzed as similar to 15 mm diameter. Peripheral blood was collected every other day, 264
210 the mouse experiment described above. lysed with ACK lysis buffer, then stained for AQUA (Invitrogen), 265
anti-human CD45 (clone HI30; BD Pharmingen), and anti- 266
211 Intracellular cytokine staining human CD8 (clone RPA-T8; BD Pharmingen). 267
212 OT-1 BTLA KO T cells overexpressing BTLA WT or mutants were
213 re-activated with either dendritic cells pulsed with OVA peptide Vaccination model 268
214 (SIINFEKL; American peptide) or dendritic cells alone at ratio of C57BL/6J mice were intravenously administered 0.5 106 269
215 1:40 in the presence of BD GolgiStop (according to the manu- nave pmel-1 or OT-I T cells, and vaccinated with gp100 peptide 270
216 facturer's instructions; BD Pharmingen). After 4 hours, the cells or OVA peptide (100 mg) together with anti-CD40 (50 mg) and 271
217 were xed and permeabilized using BD Cytox/Cytoperm kits imiquimod (50 mg). Recombinant human IL2 at 1.2 106 IU was 272
218 (according to the manufacturer's instructions; BD Pharmingen), administered once, and 6 105 IU twice daily for the next 2 days 273
219 and subsequently stained with anti-mouse IFNg (clone XMG1.2; (i.p.). Peripheral blood was collected every other day to determine 274
220 BD Pharmingen) and anti-mouse TNFa (clone MP6-XT22; BD the frequency of circulating pmel or OT-I T cells. Mice were 275
221 Pharmingen). boosted with gp100 or OVA peptide following the contraction 276
phase and peripheral blood was collected every other day. Mice 277
222 Cytokine multiplex assays were sacriced on day 120, and splenocytes were isolated to 278
223 Murine OT-1 BTLA KO cells overexpressing BTLA WT or determine the presence of pmel T cells. 279
224 mutants were restimulated with either 10 ng/mL anti-mouse CD3
225 (Clone 145-2C11, BD Pharmingen) alone or with recombinant Animals 280
226 mouse HVEM-Fc (R&D Systems) plate-bound for 24 hours. NOD-scid IL2Rgammanull (NSG) mice were purchased from the 281
227 Supernatants were collected to quantify the secreted cytokines Jackson Laboratory. OT-1 BTLA KO C57BL/6 and Pmel BTLA KO Q5 282
228 using a MILLIPLEX MAP Mouse CD8 T Cell Magnetic Bead Panel C57BL/6 mice were kindly provided from Dr. Roza Nurieva. Pmel 283
229 (Millipore). BTLA WT C57BL/6 mice were kindly provided by Dr. Willem 284
Overwijk. C57BL/6 mice were purchased from Charles River 285
230 Killing assays Laboratories. All mice were housed in a specic pathogen-free 286
231 T cells were cocultured with tumor cells labeled with facility at The University of Texas MD Anderson Cancer Center. 287
232 eFluor670 at ratio of 1:1, 1:3, and 1:10. After 3 hours, the cells Animal protocols were approved by The University of Texas MD 288
233 were xed and permeabilized using BD Cytox/Cytoperm Anderson Cancer Center [#00001229 (RN)]. 289
www.aacrjournals.org Clin Cancer Res; 2017 3

Ritthipichai et al.
292 Statistical analyses

293 Statistical analyses were performed using GraphPad Prism and
294 the R system. For all survival curve analysis data, a log-rank test
295 was used to compare distribution of the two groups. We applied
296 Linear models and empirical Bayes methods to compare the
297 differential protein expression from RPPA datasets. Differences
298 in tumor cell death of B16OVA and B16F10 and the percentages of
299 positive virally transduced mouse T cells producing IFNg and
300 TNFa were analyzed using a two-way ANOVA, and a two-tailed
301 Student t test was used to determine statistical signicance for all
302 other analyses.
303 Results
304 High expression of CD8a and BTLA correlates with an improved
305 survival of stage III metastatic melanoma patients
306 To investigate whether BTLA is associated with melanoma
307 patient survival, we conducted a KaplanMeier survival analysis
308 in stage III metastatic melanomas according to gene expression
309 data in tumor tissues from TCGA (The Cancer Genome Atlas;
310 ref. 24). We found that patients expressing high transcript levels of
311 either CD8a or BTLA had much better survival as compared with
312 either CD8a low or BTLA low, respectively (CD8a high vs. CD8a
313 low, P 0.0007, N 42; BTLA high vs. BTLA low, P 0.001, N
314 42; Fig. 1A and B). When both markers were analyzed together, the
315 association of CD8a high and BTLA high conferred the greatest
316 survival benet as compared with other combinations (CD8a
317 high BTLA high vs. CD8a low BTLA low, P 0.0006, N 98) (Fig.
318 1C). BTLA can be expressed by immune cells other than T cells
319 such as NK cells, B cells, or dendritic cells, with the highest levels
320 found in B cells (5). Interestingly, we did not observe improved
321 survival in patients with high BTLA expression when associated
322 with either high NK cells (identied by the expression of NCR1) or
323 B cells (CD19; Supplementary Fig. S1A and S1B). These data
324 suggest that high BTLA expression in association with high CD8
325 signal is associated with improved melanoma patient survival.
326 The coexpression of CD8 and BTLA cannot be inferred by gene
327 expression proling from tumor tissue; however, the improved
328 survival benet measured in conjunction with BTLA and CD8
329 expression is not seen when BTLA is evaluated in conjunction with
330 markers from other cell populations known to express BTLA.
331 These data lend support to our hypothesis that CD8BTLA TILs
332 exert efcient antitumor control based on our previous observa-
333 tion that this T-cell population correlated with better response to
334 TIL ACT (4).
335 CD8BTLATIL subset exhibits greater in vivo tumor control

336 It has been noted that more differentiated T cells secrete more Figure 1.
337 cytotoxic and cytolytic proteins compared with less-differentiated Correlation of BTLA and CD8a coexpression with overall survival in stage III
338 T cells (25). Thus, we conducted both in vitro and in vivo tumor melanoma. KaplanMeier survival curves in stage III metastatic melanoma from Q6
339 control studies to compare the killing capacity of the BTLA and The Cancer Genome Atlas (TCGA) consortium depicts: (A) CD8a expression;
CD8a high versus CD8a low (B) BTLA expression; BTLA high versus BTLA low (C)
340 BTLA CD8 TIL subsets. To determine CTL-mediated tumor Combined CD8 and BTLA expression; CD8a high BTLA high versus CD8a low
341 killing and ensure an equal tumor-specic population of both BTLA high versus CD8a high BTLA low versus CD8a low BTLA low. Total number
342 BTLA subsets, MEL 526 melanoma tumor cells expressing the of patients 98, (high- above median, low-below median). Statistical
343 MART-1 antigen were cocultured with either sorted MART-1 signicance was determined using a log-rank. (P < 0.001 and P < 0.0001).
344 recognizing (tetramer positive) CD8BTLA (CD8MART-
345 1BTLA) or CD8BTLA (CD8MART-1BTLA). We found
346 comparable MART-1 antigen-specic tumor killing ability after ability was observed using bulk nonantigen-restricted, sorted 351
347 a short term (3 hours) TIL and tumor coincubation between the BTLA subsets in a third TIL line (Fig. 2A, right, TIL #2549). As 352
348 BTLATIL and BTLATIL subsets in two TIL lines (Fig. 2A, left we did not observe a difference in in vitro killing between the two 353
349 TIL#2559; middle, TIL #2765). In addition, comparable killing subsets, but have demonstrated a better clinical outcome in 354

Figure 2.
CD8BTLA TIL demonstrate a
superior antitumor effect in vivo. A,
MART1-reactive CD8 TIL (left and
middle) and TIL 2549 (right) were
sorted into BTLA and BTLA
subsets. MEL 526 (melanoma tumor
expressing MART-1 antigen, left and
mid graph) or autologous tumor line
2549 (right graph) were stained with
eFluor670 and cocultured with TILs at
the following TIL-to-tumor cell ratios
(1:10, 1:3, and 1:1). Tumor cell death is
measured by the percentage of
caspase-3positive cells. B, Ten
million sorted CD8BTLA or sorted
CD8BTLA TILs were intravenously
injected into tumor bearing mice
previously subcutaneously implanted
with either MEL 526 or autologous
melanoma tumor line 2549. Tumor
burden was measured using calipers
and diameter graphed as mm2. C, Bar
graph shows the percentage of
CD45CD8 in the peripheral blood
on days 2, 4, 6, and 8 post-adoptive
transfer in the same experiment
described in B. N 58 animals per
group. , P < 0.05; , P < 0.001;

, P < 0.0001. All values in gure are
expressed as mean SEM. P values
were calculated using a two-tailed
Student t test.
357 patients infused with more CD8BTLA TILs, we next determined (2549; P 0.06 on day 2; Fig. 2C, right). In summary, these data 379
358 whether this subset could exhibit better in vivo tumor control. suggests that the CD8BTLA and CD8BTLA TIL subsets are 380
359 Immunodecient NOD-scid IL2Rgammanull mice (NSG) were equally able to directly kill tumor targets in a short-term in vitro 381
360 engrafted with 5 106 MEL 526 human melanoma tumor cells assay. However, the BTLA-positive subset provides superior in vivo 382
361 for 10 days prior to adoptive transfer of 1 107 human tumor control and tends to persist better following TIL transfer. 383
362 CD8MARTBTLATILs or CD8 MARTBTLATILs. Tumor bur-
363 den was measured every other day and transferred TILs were Shorter target seeking but longer target killing time for 384
364 quantied from peripheral blood based on the expression of CD8BTLA TIL subset 385
365 CD45 and CD8. We observed that the CD8BTLA TIL subset As demonstrated above, the CD8BTLA subset provides sig- 386
366 exhibited signicantly better tumor control on day 14 as com- nicantly better tumor control than its CD8BTLA counterpart 387
367 pared with its BTLA counterpart in NSG mice treated with either in vivo; however, this difference is not observed in an in vitro 388
368 MART-1 tumor antigenrestricted TIL line [2559 MART; P setting. Because our previous in vitro tumor killing experiments 389
369 0.002 (Fig. 2B, left) and 2765 MART; P 0.042 (Fig. 2B, were conducted using population assays and for only 3 hours, this 390
370 middle)] as well as in a nontumor antigenrestricted setting limited our ability to track T-cell fate following tumor target cell 391
371 (2549; P 0.049; Fig. 2B, right). In addition, we found that the interactions. To further understand the behavioral difference 392
372 level of the CD8BTLA TIL subset in the peripheral blood was between the CD8BTLA and CD8BTLA subsets in mediating 393
373 signicantly higher than the CD8BTLA subset early after ther- tumor killing, we utilized Timelapse Imaging Microscopy In 394
374 apy in mice treated with antigen-specic TIL lines [2559 MART; Nanowell Grids (TIMING), to study the dynamic interactions 395
375 P 0.039 on day 4, (Fig. 2C, left) 2765 MART; P 0.0021 and between individual tumor targets and effector T cells in high- 396
376 0.02 on day 2 and 4, respectively (Fig. 2C, middle)], but not in throughput (26, 27). To this end, labeled tumor cells and TILs 397
377 those treated with the nonrestricted antigen-specic TIL line were loaded onto the nanowell chip, consisting of 28,224 wells 398

Ritthipichai et al.
401 regularly separated in 7 7 blocks, and the interactions were while the BTLA subset achieves higher killing when more targets 462
402 quantied at two separate effector-to-target cell ratios of 1:1 and are present in the well (1:2). We reasoned that this situation could 463
403 1:2. This assay allowed us to dissect the kinetics of T-cell killing by be explained by a differential ability for serial killing, or the ability 464
404 calculating the following sequential parameters: (i) Time needed to kill a second target, which can only be detected if there is more 465
405 to establish conjugation between the T cell and tumor target than one target in the well therefore at a 1:2 ratio (Fig. 3E). 466
406 (tseek), (ii) duration of the contact between the T cell and the
407 tumor target (tcontact), and (iii) time between the rst T-cell contact Improved survival of the CD8BTLA TIL subset following 467
408 with the tumor cell and tumor cell apoptosis (tdeath; Fig. 3A). killing of a target 468
409 Interestingly, the CD8BTLA subset was more efcient in tumor After activation, T cells can be eliminated through the process of 469
410 seeking at effector-to-target cell ratios of 1:1 (N 3,319) as the activation-induced cell death (AICD). The ability of the 470
411 time utilized to make rst contact with tumor cells was signi- CD8BTLA subset to kill multiple targets could be linked to an 471
412 cantly less than that of the CD8BTLA subset (P < enhanced ability to survive AICD after completing its effector 472
413 0.0001; Fig. 3B, left). This difference was not observed when 2 function. To test this hypothesis, we quantied effector T-cell 473
414 targets were present in the well (1:2, P 0.22) (Fig. 3B, left). It is death after a tumor killing event. We found that in fact, 474
415 possible that loading 2 targets in each nanowell rendered the CD8BTLA TILs are more susceptible to undergo apoptosis as 475
416 distance to travel to meet each target too short to be able to compared with their CD8BTLA TIL counterpart (P < 0.01; Fig. 476
417 measure a difference in the ability of T-cell subsets to seek the 3F). These data demonstrate that the CD8BTLA subset survives 477
418 target. However, in comparison with CD8BTLA TILs, individual better after killing a tumor target and thus is able to sustain its 478
419 CD8BTLA TILs spent longer time in contact with a tumor cell cytotoxic functionality and eliminate additional tumor cells. In 479
420 target and induced apoptosis with slower kinetics at both E:T summary, these results argue that both subsets kill equally well in 480
421 ratios studied (tcontact; 1:1 and 1:2, P < 0.0001, tdeath; 1:1 and 1:2, a short-term killing assay (250 minutes) but the differences 481
422 P < 0.0001; Fig. 3B, middle and right, respectively). Overall, emerge when the T-cell and tumor coincubation is prolonged to 482
423 individual CD8BTLA TILs found their target faster, but required 8 hours wherein the CD8BTLA TIL subset is found to have an 483
424 longer durations to complete tumor cell killing (Supplementary increased propensity to survive a killing event and therefore 484
425 Movie S1 and S2). function as serial killers, thus conrming that the CD8BTLA 485
TIL subset is qualitatively better consistent with the in vivo results 486
426 CD8BTLA TIL subset is characterized by a heightened ability (Supplementary Movie S3). 487
427 to kill multiple targets
428 We next examined whether one subset was more potent in its Memory recall response is defective in BTLA-decient T cells 488
429 overall tumor killing capacity by evaluating tumor target cell Our data suggest a difference in survival of BTLA antitumor 489
430 survival over the 8-hour coculture period. Overall, both T-cell CD8 T cells rather than a change in killing potential. We next 490
431 subsets killed 18% of the tumor targets at an E:T ratio of 1:1 (Fig. sought to evaluate the long-term fate of CD8BTLA antigen- 491
432 3C, red inner circle). However, at the 1:2 ratio, the CD8BTLA specic T cells after in vivo antigenic challenge in an immuno- 492
433 subset was able to kill a total of 21% of the tumor targets upon competent animal. Our study of the expression of BTLA in human 493
434 contact as opposed to only 14% for the CD8BTLA subset (Fig. and mouse CD8 T cells showed a different expression pattern 494
435 3C, red and green sections, outer circle). Second, when presented (Supplementary Figs. S2 and S3). Murine nave CD8 (CD44 low 495
436 with two tumor targets, the CD8BTLA subset was twice as likely CD62L high) are negative for BTLA, but expression of BTLA is 496
437 to kill both targets (14% for the BTLA vs. 7% for the acquired as the cells differentiate to memory (CD44 high) while 497
438 BTLA; Fig. 3C). human nave CD8 cells (CCR7, CD45RA) are positive for BTLA 498
439 Examination of the kinetics of tumor killing offered clues to and expression is progressively lost as the CD8 cells differentiate 499
440 understand the differences in the overall killing potential of the to terminal effector cells (EMRA, CCR7, CD45RA). However, 500
441 two subsets. The analysis of the full 500-minute assay revealed a memory stages of differentiation are positive for BTLA in both 501
442 different killing pattern early after tumor encounter (rst 250 mouse and human. On the basis of this, we reasoned that a 502
443 minutes) in comparison with the second half of the incubation vaccination model would be the most appropriate in vivo antigen 503
444 (last 250 minutes). A close look at the rst 250 minutes demon- trigger to measure the role of BTLA on the function of CD8. We 504
445 strated that the CD8BTLA subset was more effective in tumor aimed to measure the impact of BTLA expression on newly 505
446 killing than the CD8BTLA subset as the survival of the con- generated memory CD8 T cells on their capacity to respond to 506
447 tacted tumor targets dropped signicantly faster when coincu- a second antigen exposure (recall). In this study, we sought to 507
448 bated with CD8BTLA TILs at effector-to-target cell ratios of 1:1 determine the role of BTLA in the persistence of antigen-specic 508
449 and 1:2 (left, 1:1, P < 0.03; right, 1:2, P < 0.0001; Fig. 3D). CD8 T cells in vivo after antigenic stimulation. We used TCR 509
450 However, the overall percentage of killed targets at both ratios transgenic CD8 T cells that are either WT or KO for BTLA and 510
451 at the 250 minutes mark is the same between both TIL subsets. study their response to immunization and memory-recall 511
452 Therefore, the killing potential of the two subsets is comparable in response using a mouse vaccination model as described previ- 512
453 the rst 250 minutes but their kinetics of killing are different. ously (28). Splenocytes (5e5) from either Pmel-1 WT or Pmel-1 513
454 Over the last 250 minutes of the assay, the picture changes (Fig. BTLA KO (recognizing gp100 peptide) were adoptively trans- 514
455 3E). The blue curve (BTLA) now dips below the red curve ferred into C57BL/6 recipient mice. On the following day, mice 515
456 (BTLA), signifying that the BTLA subset is catching up with were vaccinated with gp100 peptide together with anti-mouse 516
457 the BTLA subset in terms of the speed at which it kills (E:T ratio of CD40. Imiquimod cream 5% was also applied on the vaccination 517
458 1:1, P 0.54), or takes a signicant lead (E:T ratio of 1:2, P < site to boost the innate immune response. In addition, IL2 was 518
459 0.0001). It is also worth noting that very limited killing occurs also provided to support in vivo T-cell proliferation following 519
460 with the BTLA in the second half of the experiment at any ratio vaccination (Fig. 4A and B). The frequency of Pmel-1 T cells was 520

Figure 3.
CD8BTLATIL subset mediates killing of
multiple tumor targets through enhanced
survival properties. Nanowell arraybased
cytolysis assay was used to determine
tumor killing capacity at single-cell level.
Effector cell and tumor target are labeled in
different colors and loaded into the
nanowell at effector-to-target cell ratios of
1:1 and 1:2. Interaction between effector and
target cells is monitored by automated
time-lapse camera coupled with a
uorescence microscope. A, Schematic
diagram demonstrates the sequential
events that effector cells seek (tseek),
contact (tcontact), and mediate tumor cell
death (tdeath). B, Either
CD8MARTBTLA or CD8MARTBTLA
subset was coincubated with MEL 526.
Time (min) between each sequential event
is evaluated. Dot plots depict tseek (left),
tcontact (middle), tdeath (right) in
comparison between CD8BTLA (blue)
and CD8BTLA (red) subsets. All error
bars depicts the mean SEM. All P values
were calculated using a two-tailed Student
t test. (N 497). C, Donut charts
demonstrate the frequency of tumor cell
death following effector cell killing by
either CD8BTLA (left)or
CD8BTLA(right) subset. Inner circle and
outer circle depict E:T ratio of 1:1 and 1:2,
respectively. D, KaplanMeier survival
curves of T-cellcontacted tumor target
resulting in a killing event in the rst 250
minutes in comparison between
CD8BTLA and CD8BTLAsubsets at
effector-to-target cells ratios of 1:1 (left)
and 1:2 (right). E, KaplanMeier survival
curves of T-cellcontacted tumor target
resulting in a killing event in the last 250
minutes minutes in comparison between
CD8BTLA and CD8BTLAsubset at
effector-to-target cells ratios of 1:1 (left)
and 1:2 (right). Statistical signicance in D
and E was determined using a log-rank
(N 3,319; , P < 0.0001). F, Kaplan
Meier survival curves of tumor-contacted
effector cells following tumor cell death in
comparison between CD8BTLA and
CD8BTLA subsets at an effector-to-
target ratio of 1:1. Statistical signicance
was determined using a log-rank (N
3,319; , P < 0.05).

Ritthipichai et al.
523 tracked in peripheral blood after vaccination (Fig. 4C). On day 20

524 following priming, we observed a signicantly higher frequency
525 of Pmel-1 WT in peripheral blood when compared with Pmel-1
526 BTLA KO. The frequency of both Pmel-1 WT and Pmel-1 BTLA KO
527 contracted to prepriming frequency by day 30. Boost vaccination
528 was performed on day 60. We observed that Pmel-1 WT T cells had
529 a robust recall response that was absent in the Pmel-1 BTLA KO
530 group (Fig. 4C). To determine the impact on the generation of a
531 long-term memory response, we assessed the frequency of Pmel-1
532 T cells in the spleen on day 120. We found a signicantly higher
533 percentage of Pmel-1 WT T cells in the spleen as compared with
534 Pmel-1 BTLA KO T cells (Fig. 4D, P 0.038). Similar data were
535 obtained with the transfer of BTLA WT or KO OT-1 T cells and
536 vaccination with OVA peptide SIINFEKL (Supplementary Fig. S4).
537 In this context, the use of BTLA KO OT-1 T cells led to a marked
538 attenuation of the recall response, but not the complete lack
539 observed with the Pmel-1 T cells. Nonetheless, these results
540 suggest that BTLA is critical for the generation of a recall memory
541 response.
542 Dichotomous BTLA signaling: ITIM/ITSM dampens effector

543 cytokine secretion while Grb2 enhances IL2 production
544 Our in vivo experiments with human TIL and single-cell killing
545 analyses have suggested that the CD8BTLA subset is endowed
546 with a superior prosurvival function leading to better antitumor
547 activity. Conceivably, the superiority of this subset could result
548 from either (i) properties of less-differentiated T cells marked by
549 BTLA expression or (ii) signaling through the BTLA molecule
550 itself. Our vaccination study suggests a direct involvement of the
551 BTLA molecule. However, to further test the contribution of the
552 BTLA signaling, we performed functional studies of BTLA by
553 overexpressing wild-type BTLA (WT BTLA) or variants of BTLA's
554 intracellular motifs in OT-1 T cells from OT-1 BTLA KO mice. To
555 dissect the signaling contributions from the ITIM/ITSM and the
556 Grb2 motifs independently, retroviral constructs were generated
557 with point mutations by substitution of tyrosine for phenylala-
558 nine in either the Grb2-binding motif (DGrb2) or the ITIM and
559 ITSM motifs (DITSM; Fig. 5A). OT-1 BTLA KO T cells were Figure 4.
560 transduced with constructs containing WT BTLA, DGrb2, and Defective memory recall response of BTLA-decient T cells. Schematic diagram
561 DITSM as well as an empty vector control (EM). Virally transduced depicting experimental design of mouse model for vaccination. 0.5 106 (A)
562 OT-1 T cells were cocultured with either B16F10 (negative for OVA Pmel-1 Thy 1.1. wild-type splenocytes or Pmel-1 BTLA KO splenocytes (B) were
563 antigen) or B16OVA tumor cells at an effector-to-target ratio of adoptively transferred into C57BL/6 mouse recipients (i.v.; n 5 mice per
564 1:10, 1:3, and 1:1. HVEM expression on both tumor targets was group). On the following day, the recipients were vaccinated with gp100 peptide
(100 mg) together with anti-CD40 (50 mg) and imiquimod (50 mg). Recombinant
565 conrmed by ow cytometry (Supplementary Fig. S5). Indeed, the human IL2 at 1.2 106 IU was administered once, and 6 105 IU twice daily for the
566 tumor killing capacity of the TILs in this short-term in vitro assay next 2 days (i.p.). Peripheral blood was collected every other day to determine
567 was comparable regardless of the presence of WT BTLA or BTLA the frequency of circulating Pmel-1 Thy 1.1 T cells. On day 60, the mice were
568 mutants at all ratios tested (ratio 1:1, P 0.67; ratio 1:3, P 0.46; vaccinated with gp100 peptide, and peripheral blood was collected every other
569 ratio 1:10, P 0.29; Fig. 5B). We did not observe differences in the day until Pmel-1 T cells were no longer detected. On day 120, the mice were
570 number of T cells producing IFNg or TNFa among these different euthanized, and spleens were collected to determine the presence of Pmel-1 Thy
1.1 T cells. C, Plot graph depicts the percentage of CD3CD8Pmel T cells in the
571 groups (IFNg, P 0.11; TNFa, P 0.59; Fig. 5C, left). However, peripheral blood following the priming (rst peak from day 15 to day 30) and
572 the amount of effector cytokines being made by the WT BTLA- boosting (second peak from day 60 to 70). The frequency of CD3CD8PmelT
573 transduced T cells was signicantly less than that made by those cells was signicantly higher in C57BL/6 mouse recipients receiving Pmel-1 Thy
574 transduced with the empty vector alone following restimulation 1.1 wild-type splenocytes as compared with those receiving Pmel-1 Thy 1.1 BTLA
575 with dendritic cells pulsed with OVA peptide (IFNg MFI; EM vs. KO splenocytes. D, Comparison of the percentage of CD3CD8Pmel T cell in
576 WT, P 0.04, TNFa MFI; EM vs. WT, P 0.0045; Fig. 5C, right). spleen on day 120 of mice receiving either Pmel-1 Thy 1.1 wild-type splenocytes or
Pmel-1 Thy 1.1 BTLA KO splenocytes. Pmel-1 Thy 1.1 BTLA KO splenocytes failed to
577 The BTLA-mediated inhibition of IFNg and TNFa production was develop memory recall response following vaccination and boosting.
578 relieved by the disruption of the ITIM/ITSM motifs; however, it
579 was not signicantly impacted by the disruption of the Grb2
580 motif, suggesting that ITIM and ITSM motifs are mainly involved We have previously demonstrated that the CD8BTLATIL 584
581 in regulating the amount of effector cytokines produced following subset had an improved proliferative capacity in response to IL2 585
582 TCR triggering. (14). Thus, we sought to determine whether BTLA signaling 586

Figure 5.
BTLA signaling motifs show no effect
on tumor killing, while Grb2 motif
augments IL2 production and T-cell
proliferation. A, Schematic diagram
depicts the structure of BTLA WT
(left), BTLADGrb2 (middle), and
BTLADITSM (right). Signaling motifs
with modied Tyrosine to
Phenylalanine are indicated by a
dotted pattern over a black
background. A table summarizing the
phenotype observed with the
expression of BTLA or of the different
BTLA constructs is presented on the
right. B, B16 OVA (mouse melanoma
tumor positive for OVA) or B16F10
(mouse melanoma tumor negative for
OVA) were stained with eFluor670
and cocultured with OT-1 BTLA KO T
cells overexpressing WT BTLA or
BTLA mutants at the following T-cell-
to-tumor cell ratios (1:10, 1:3, and 1:1).
Tumor cell death is depicted by the
percentage of caspase-3positive
cells. N 3 independent experiments.
C, OT-1 BTLA KO T cells
overexpressing WT BTLA or its
variants were restimulated with
dendritic cells pulsed with OVA
peptide. TNFa and IFNg production by
virally transduced OT-1 BTLA KO T
cells was evaluated by intracellular
staining. Bar graph depicts the
percentage of positive cells (left) and
mean uorescence intensity (MFI;
right). Each bar represents three
independent experiments (two-way
ANOVA; , P < 0.05). D, OT-1 BTLA KO
T cells overexpressing WT BTLA or its
variants were labeled with eFluor670
and restimulated with dendritic cells
pulsed with OVA peptide. Cell
proliferation was determined by the
dilution of eFluor670. Histogram plots
of eFluor670 demonstrate
proliferation of OT-1 BTLA KO T cells
variants. Bar graph depicts MFI of
virally transduced T cells in the same
experiment shown in the left. N 3 , P
< 0.05; , P < 0.001, , P < 0.0001. All
error bars depicts the mean SEM. All
P values were calculated using a two-
tailed Student t test. E, Virally
transduced OT-1 BTLA KO T cells were
stimulated with plate-bound anti-
mouse CD3 and HVEM Fc.
Supernatants were assessed for IL2
production using by MILLIPLEX MAP
Mouse CD8 T Cell Magnetic Bead
Panel Assays. Each bar graph
represents two independent
experiments. , P < 0.05; , P < 0.001.
All error bars depicts the mean SEM.
All P values were calculated using a
two-tailed Student t test.

Ritthipichai et al.
589 motifs could play a role in T-cell proliferation. OT-1 BTLA KO T BTLA-HVEM axis in human TILs selectively suppresses Akt and 650
590 cells overexpressing BTLA WT or mutants were labeled with the NFkB pathways but enhances Src pathway 651
591 cell proliferation dye eFluor670 and restimulated with dendritic To exclude the bias of overexpression of WT BTLA and genet- 652
592 cells pulsed with OVA peptide for two days. T-cell proliferation ically modied BTLA in BTLA knockout mouse, we further inves- 653
593 was comparable between control and WT BTLA groups. (MFI: WT tigated BTLA signaling pathway in human TILs, which is more 654
594 vs. EM; P 0.30; Fig. 5D, histogram). On the other hand, subtle physiologically and clinically relevant to our observation in our 655
595 differences are appreciable between T cells expressing the different adoptive T-cell therapy clinical trial. Sorted CD8BTLA human 656
596 BTLA constructs. We observed that OT-1 BTLA KO T cells expres- TILs were stimulated with plate-bound anti-human CD3 at con- 657
597 sing DITSM had a lower mean uorescence intensity (MFI) of the centrations of 10, 30, 100, 300, and 1,000 ng/mL with or without 658
598 eFluor670 dye as compared with the empty vector control which HVEM-Fc for 8 hours and proteins extracted from cell lysates were 659
599 is indicative of a more robust proliferation (MFI: DITSM vs. EM; used to perform RPPA in 5 separate patient TIL samples. We 660
600 P 0.012, DITSM vs. WT; P 0.0057; Fig. 5D). On the contrary, observed a general decrease in differentially phosphorylated 661
601 attenuation of T-cell proliferation was observed in T cells expres- protein changes in several signaling pathways when T-cell acti- 662
602 sing a disrupted Grb2 motif (DGrb2), (MFI: DGrb2 vs. DITSM; P vation happened in the presence of HVEM. These included the 663
603 0.0003, DGrb2 vs. EM; P 0.0008, DGrb2 vs. WT; P 0.0009; Fig. MAPK kinase pathway (pP38 at T180; P 2.08 109, pP90RSK 664
604 5D). These data suggest that the T-cell proliferation post TCR at T573; P 3.26 104, pS6 at S235; P 1.68 102), NFkB 665
605 triggering is regulated positively by the Grb2 motif and negatively pathway (pNFkB p65 at S536; P 3.15 102), the Akt pathway 666
606 by ITIM/ITSM motifs. (pAKT at S473; P 9.6 103), and the b-catenin pathway (GSK- 667
607 Our previous report demonstrated that CD8BTLA human 3a-b pS21; P 9.6 103; Fig. 6B and C; Supplementary Table 668
608 TILs produce more IL2 upon activation (14). Thus, we further S5). Inhibition of these positive signaling pathways clearly sup- 669
609 investigated whether BTLA signaling could be responsible for IL2 ports the role of BTLA as a coinhibitory molecule. Interestingly, we 670
610 secretion. OT-1 BTLA KO T cells overexpressing WT BTLA or its found a signicant elevation of Src phosphorylation at S416 (pSrc 671
611 mutants were restimulated with anti-CD3 in the presence of at S416; P 3.36 106) when the T-cell activation happened in 672
612 HVEM-Fc fusion protein to engage the BTLA molecule, and IL2 the presence of HVEM. Our results suggest that the TCR signaling 673
613 secretion was assessed. Indeed, we found that IL2 production was pathway is not completely suppressed by BTLA, but is specically 674
614 signicantly increased in activated T cells transduced with the attenuated in certain pathways as indicated above and specically 675
615 BTLA WT and DITSM constructs, but not in DGrb2 and the empty potentiated in very select pathway(s). Unexpectedly, we found 676
616 vector. This suggests that the BTLA-dependent IL2 production was that phosphorylation of HER2 at tyrosine 1248 was prominently 677
617 mediated through Grb2 motif, independently of the ITIM/ITSM increased in an anti-CD3 dose-dependent manner regardless of 678
618 motifs (WT vs. EM; P 0.02, DITSM vs. EM; P 0.005, WT vs. the presence of HVEM. This strengthens the notion that the BTLA/ 679
619 DGrb2; P 0.02, DITSM vs. DGrb2; P 0.01, EM vs. Grb2; P HVEM axis acts on specic targets. To further comprehensively 680
620 0.79, WT vs. DITSM; P 0.32; Fig. 5E). These data highlight that understand the downstream signaling pathway of human BTLA, 681
621 Grb2 signaling contributes to IL2 production following BTLA we generated the signaling network of proteins signicantly 682
622 ligation during T-cell activation. A summary of the phenotypes changed during HVEM ligation using Ingenuity Pathway Analysis 683
623 seen with the expression of BTLA or its variants is presented in Fig. (IPA). We observed that Src signaling node was exclusively clus- 684
624 5A (right). tered and separated from Akt, NFkB, and b-catenin signaling 685
nodes. This suggests that the Src signaling pathway is likely not 686
625 Signaling downstream of mouse BTLA or minimally interfered by SHP1/2 (Fig. 6D). 687
626 To identify proteins activated downstream of BTLA, we
627 employed RPPA, a high-throughput method developed for func-
628 tional proteomic studies. OT-1 BTLA KO mouse T cells over-
Discussion 688
629 expressing WT BTLA or BTLA mutants were stimulated with anti- Our recent report demonstrated that the CD8BTLA TILs are 689
630 CD3 with or without HVEM-FC for 8 hours. The full list of tested less differentiated, respond better to IL2, and persist longer in the 690
631 proteins can be found in Supplementary Table S3. The protein patient postinfusion (14). In the current study, we shed light on 691
632 expression levels found in activated T cells transduced with BTLA the dichotomy of the signaling downstream of BTLA and highlight 692
633 WT was used as a reference to compare the differential protein a role for BTLA in the development of CD8 T-cell memory-recall 693
634 changes in DGrb2 and DITSM. The protein expression prole of and the survival of effector memory CD8 T cells sustaining their 694
635 the T cells expressing the BTLA variants were also compared with antitumor function. 695
636 that obtained with the empty vector (Supplementary Table S4). We observed that the CD8 BTLA and CD8 BTLA subsets 696
637 We observed that the phosphorylation of Akt at T308 as well as the had comparable in vitro killing, which did not explain the supe- 697
638 phosphorylation of one of its substrates, pPRAS40 at T246, were riority of the CD8 BTLA subset in controlling disease in 698
639 signicantly attenuated in DGrb2 in comparison with BTLA WT patients. The use of a single-cell nanowell-based cytolytic assay 699
640 (pAkt T308; P 0.045, pPRAS40 T246; P 0.007; Fig. 6A, left; helped elucidate fundamental differences between the two sub- 700
641 Supplementary Table S4) (29). As expected, the disruption of sets. Importantly, the results demonstrated that both subsets 701
642 ITIM/ITSM motif resulted in a remarkable enhancement of the efciently kill a rst target, but the CD8BTLA subset is more 702
643 phosphorylation of several proteins such as Src, Chk1, Chk2, as likely to survive after this killing event and kill another target, thus 703
644 well as members of the Wnt pathway GSK-3b, and of b-Catenin at providing a rationale for the improved in vivo efcacy of the 704
645 T41 and S45 (pSrc at S527; P 0.005, pA-Raf at S299; P 0.01, CD8BTLA TILs. 705
646 and pC-Raf at S338; P 0.02, pChk1 at S286; P 0.01, pChk2 at The defective recall response seen in BTLA KO antigen-specic 706
647 T68; P 0.02, GSK-3b at S9; P 0.04, b-Catenin at T41 and S45; T-cell in vivo models used contrasts with previous literature. A 707
648 P 0.04; Fig. 6A, right; Supplementary Table S4). publication by Krieg and colleagues evaluates the response of the 708

Figure 6.
BTLA-HVEM signaling axis suppresses
MAPK, Akt, and NFkB pathways, but
selectively augments the Src pathway.
A, OT-1 BTLA KO T cells
variants were restimulated with plate-
bound anti-CD3 and HVEM-Fc for 8
hours prior to harvest. Cells were lysed
and the protein supernatant was
collected to perform RPPA. Volcano
plots depict fold change of proteins
with the following comparisons:
DGrb2 versus WT (left), DITSM versus
WT (middle), and DITSM versus EM
(right). Data shown represent two
independent experiments. P < 0.05. P
values were calculated using Linear
models and empirical Bayes methods.
B and C, Sorted CD8BTLA TIL were
stimulated with plate-bound anti-CD3
(0, 10, 30, 100, 300, and 1,000 ng/mL)
alone or with HVEM-Fc for 8 hours
prior to harvest. Cells were lysed and
the protein supernatant was collected
to perform RPPA. B, Volcano plot
depicts fold change of proteins in
CD8BTLATIL upon T-cell activation
with anti-CD3 alone (left), anti-CD3
HVEM (middle), and anti-CD3 in
comparison with anti-CD3 HVEM
(right). C, Bar graph demonstrates
proteins that signicantly change in
comparison between anti-CD3
activation alone (red) and anti-CD3
HVEM ligation (blue). D, Signaling
network from the proteins that
signicantly change in C were
clustered by Ingenuity Pathway
Analysis. N 5, P < 0.05. P values were
calculated using Linear models and
empirical Bayes methods.
711 CD8 BTLA-KO OT-1 T cells in a vaccination model and claims the fact that there are twice as many CD8 OT-1 BTLA-KO T cells 715
712 that there is more efcient memory formation in the BTLA-KO than WT counterpart in the spleen 30 days after the primary 716
713 OT-1 T cells than their WT counterpart (30). This claim is based on stimulation even though the BTLA-KO OT-1 subset peaked at 717

Ritthipichai et al.
720 lower frequency in the early days of the primary response. The memory CD8 T cells distinguishing them from nave and effector 782
721 BTLA-KO OT-1 also had a slightly lower fold expansion early subsets, and was found to play a role in survival of the memory 783
722 (day 4) during the secondary expansion (7-fold vs. 10-fold) CD8 subset conducive to the establishment of a long-lived 784
723 following boosting with peptide-pulsed DC. This is in contrast memory pool (33). Our ndings of the better survival of the 785
724 with the data obtained when boosting with an infectious agent CD8BTLA TIL subset after a killing event are consistent with a 786
725 expressing OVA, LM-OVA, where the BTLA-KO OT-1 expand more prosurvival advantage. A recent study indicated that increased 787
726 than the BTLA WT OT-1 at day 5 (91-fold vs. 191 fold). Unfor- SRC was strongly associated with a superior bioenergetic capacity, 788
727 tunately the experiment was not carried out longer. The authors which helped improve T-cell survival and motility under hypoxic 789
728 conclude that BTLA KO OT-1 can form memory, and that the conditions (34). The intrinsic properties of this subset provide an 790
729 amplitude of the recall response may depend on the type of intriguing possibility for why infusion of large numbers of 791
730 antigenic challenge used. Interestingly, another study utilizing CD8BTLATILs positively correlates with clinical response to 792
731 BTLA KO animals and LM-OVA infection concluded that HVEM TIL ACT in metastatic melanoma patients. 793
732 expression on T cells transduces a survival signal through inter- We have found that a BTLA-dependent potentiation of IL2 794
733 action with BTLA expressed on other cells in the host and that secretion entirely depends on Grb2 motif. Disruption of the ITIM 795
734 interaction was required for CD8 T-cell memory generation (31). and ITSM motifs did not alter the levels of IL2 induced by BTLA, 796
735 There are a few key differences between our vaccination model suggesting a signaling pathway independent of the proinhibitory 797
736 and the reported studies. First of all, the adoptive cell transfer in inuence of ITIM and ITSM. Our ndings are consistent with 798
737 the article by Krieg and colleagues is performed to allow compe- previous reports that have shown that Grb2-linked SLP-76 and 799
738 tition between the cell subsets in the host. The authors actually Vav interaction are involved in IL2 production, and that recruit- 800
739 transfer both BTLA WT OT-1 and BTLA KO OT-1 T-cells at a 1:1 ment of Grb2 is essential for CD28-induced IL2 production 801
740 ratio to BTLA WT hosts and vaccinate the animals one day later (19, 35, 36). Our current study reveals that BTLA engagement in 802
741 with peptide-pulsed dendritic cells. While these experiments were the context of TCR stimulation results in IL2 production in a 803
742 designed to test BTLA's function, the known expression of BTLA's manner similar to CD28 which positions BTLA as both a coin- 804
743 receptor, HVEM, on activated T cells, and its ability to transduce a hibitory and costimulatory molecule. The in vivo relevance of 805
744 survival signal by interactions in trans may become a confounding BTLA-dependent IL2 production in the context of T-cell activation 806
745 factor. In this system, it is possible that BTLA expressed on BTLA warrants further study. Autocrine IL2 production by CD8 T cells 807
746 WT OT-1 may have interacted with HVEM on both transferred has been shown to be essential for secondary expansion of CD8 808
747 subsets which could have delivered a survival signal potent memory T cells which could potentially explain the lack of 809
748 enough to limit the contraction phase and enhance memory secondary expansion seen in BTLA KO cells after boosting with 810
749 formation for both subsets. The amplitude of the memory gen- the vaccinating antigen (37). The prosurvival properties conferred 811
750 eration in this system could be controlled by the strength of TCR by BTLA on CD8 T cells may come from the interaction of BTLA 812
751 signal which clearly will be stronger in BTLA KO OT-1 as all studies with HVEM on activated T cells as it was demonstrated for CD4 813
752 are in agreement that BTLA suppresses TCR signaling. murine T cells (38, 39) However the HVEM interaction with its 814
753 Our experiments were designed to study the response of the two alternative ligand LIGHT rather than BTLA has been implicated in 815
754 subsets separately, in different animals. Our data rather shows furthering CD4 T-cell activation and survival (39). In our experi- 816
755 BTLA-mediated survival of T cells following effector function, ments, the absence of BTLA may render HVEM available to bind to 817
756 probably due to dampening of TCR signaling and prevention of its alternative ligand LIGHT to provide costimulatory signaling to 818
757 AICD. We believe that BTLA acts as a rheostat reducing TCR T cells; however, this mechanism was not sufcient to rescue the 819
758 signaling during strong or chronic antigenic stimulation while establishment of memory cells able to respond to a recall antigen 820
759 also promoting cell survival due to the presence of both activating stimulation. 821
760 and inhibitory signaling motifs in its intracellular signaling Conversely, we did not observe any major differences in in vitro 822
761 domain. Our vaccination was administered by injection of the killing capacity and cytotoxic cytokine production between BTLA 823
762 cognate peptide and anti-CD40 in saline subcutaneously, with KO T cells versus BTLA KO T cells overexpressing BTLA WT or its 824
763 topical application of the TLR 7 agonist imiquimod on the mutants. This suggests that BTLA signaling does not affect tumor 825
764 injection site and IP IL2. This vaccination strategy, optimized by killing capability. Our ndings are consistent with the previous 826
765 our collaborator Drs. Hailemichael and Overwijk, results in a report showing that the BTLA blockade in gdT cells had no effect 827
766 powerful activation of the antigen-specic T-cell response (28). on the tumor lysis (40). 828
767 This stimulation produces a robust recall response in WT OT-1 We did not observe a signicant impact of WT BTLA when the 829
768 and Pmel T cells; however, in our hands the BTLA KO OT-1 cells molecule was reintroduced in BTLA KO T cells. However, mal- 830
769 have a reduced ability to generate a recall response and Pmel BTLA function of ITIM and ITSM motifs signicantly enhanced T cell 831
770 KO cannot recall at all. We reasoned that BTLA expression may be proliferation while Grb2 alteration reduced the proliferation. A 832
771 essential to suppress overstimulation conducive to AICD and lack of impact of BTLA on CD4 T-cell proliferative response has 833
772 allow the survival of cells to form a memory pool. The method been reported previously (12). Previous studies in both human 834
773 employed to vaccinate in the study by Krieg and colleagues, the and mouse settings indicated that CD8 T cells were intrinsically 835
774 use of peptide-pulsed DCs, may also not cause as much AICD as less susceptible to BTLA-mediated inhibition as compared with 836
775 the stimulation used in our system, thus not requiring dampening CD4 T cells (9, 41). This might explain the minimal inhibition of 837
776 of TCR stimulation by BTLA for survival. WT as compared with EM in CD8 T cells in terms of proliferation. 838
777 We have demonstrated previously that resting CD8BTLATIL We noticed that the Akt signaling pathway was remarkably 839
778 manifested enhanced mitochondrial function and spare respira- attenuated in BTLA DGrb2, while the phosphorylation of Src was 840
779 tory capacity (SRC) as compared with their CD8BTLA TIL enhanced in BTLA DITSM. This nding is consistent with a 841
780 counterpart (32). High SRC has been reported to be a feature of previous report demonstrating that ITIM and ITSM motifs of 842

845 PD-1 inhibited signals through Akt and MAPK (10). However, in Disclosure of Potential Conicts of Interest 891
846 the presence of costimulation mediated through the BTLA Grb2 No potential conicts of interest were disclosed. Q7 892
847 motif, as in the case of DITIM/ITSM, the phosphorylation of Akt

848 was unaltered, suggesting that Grb2 is not directly involved in Authors' Contributions 893
849 maintaining or augmenting Akt phosphorylation. Taken together, Conception and design: K. Ritthipichai, C. Haymaker, L.G. Radvanyi, P. Hwu, 894
850 these data suggests that the Akt pathway in BTLA was likely C. Bernatchez 895
851 targeted by SHP1/2, similar to what was found in PD-1. Development of methodology: K. Ritthipichai, L.G. Radvanyi 896
852 Overexpression of Grb2 in osteoclasts was shown to promote Acquisition of data (provided animals, acquired and managed patients, 897
provided facilities, etc.): K. Ritthipichai, W.W. Overwijk, L. Vence, 898
853 phosphorylation of Src at Y416 and the opposite result was
N. Varadarajan 899
854 obtained when Grb2 expression was disrupted (42). From our Analysis and interpretation of data (e.g., statistical analysis, biostatistics, 900
855 data, it is clear that the phosphorylation of Src increased when computational analysis): K. Ritthipichai, C. Haymaker, M. Martinez-Paniagua, 901
856 Grb2 was providing BTLA signaling in the absence of functional A. Aschenbrenner, W.W. Overwijk, L. Vence, J. Roszik, N. Varadarajan, 902
857 ITIM and ITSM motifs. This could result from either the direct L.G. Radvanyi, P. Hwu, C. Bernatchez 903
858 effect of Grb2 signal transduction or the lack of dephosphoryla- Writing, review, and/or revision of the manuscript: K. Ritthipichai, 904
C. Haymaker, M. Martinez-Paniagua, A. Aschenbrenner, W.W. Overwijk, 905
859 tion normally caused by SHP1/2 via ITIM and ITSM motifs. As the
J. Roszik, N. Varadarajan, P. Hwu, C. Bernatchez 906
860 phosphorylation of Src is not signicantly inuenced by the ITIM/ Administrative, technical, or material support (i.e., reporting or organizing 907
861 ITSM cosignaling (DGrb2), we conclude that it is likely to be Grb2- data, constructing databases): X. Yi, M. Zhang, C. Kale, Y. Hailemichael 908
862 mediated Src activation. Study supervision: R. Nurieva, L.G. Radvanyi, C. Bernatchez Q8 909
863 Our data of BTLA signaling in mouse T cells was found to be

864 consistent with changes observed when activated human Acknowledgments 910
865 CD8BTLATILs were costimulated by HVEM. Indeed, we The authors thank the melanoma surgical staff at MD Anderson Cancer 911
866 observed an attenuation of MAPK, NFkB, and Akt signaling Center. We appreciate help from TIL laboratory for processing tumor samples. 912
867 proteins, but phosphorylation of Src was enhanced when human We are thankful for the staff at the MD Anderson Cancer Center Flow Cytometry 913
Core Facility for technical assistance with cell sorting. We are grateful to Drs. 914
868 TILs were stimulated with anti-CD3 and HVEM as compared with
Weiyi Peng and Ondrej Havranek for guidance on experimental design. 915
869 CD3 alone. This suggested that the downstream signaling path-
870 way of BTLA in mice and humans possibly share similar down-
871 stream signaling targets. Grant Support 916
This work was supported by the National Cancer Institute (NCI) grants 917
872 Overall, our study sheds light on a dual role of BTLA as both a
R01-CA111999 (to P. Hwu), R01CA174385 (to N. Varadarajan) and 918
873 costimulatory and coinhibitory molecule. This observation is 1R21CA178580-01 (to C. Bernatchez). STR DNA ngerprinting was done 919
874 supported by a study reporting that the gene expression prole by the CCSG-funded Characterized Cell Line Core at MD Anderson, NCI 920
875 of CD4 T cells activated with CD3 and BTLA engagement mimics grant P30CA016672. This grant also supported the the Flow Cytometry Core 921
876 the prole induced by costimulatory molecules (12). In our Facility that was used for cell sorting and the Functional Proteomics Reverse 922
877 hands, the integration of the positive and negative signals trans- Phase Protein Array (RPPA) Core. This work was further supported by the UT 923
Health Innovation for Cancer Prevention Research Pre-doctoral Fellow, The 924
878 duced by BTLA promotes IL2 secretion while reducing effector
UT School of Public Health-Cancer Prevention and Research Institute of 925
879 cytokine production and proliferation in certain contexts. In Texas grant RP160015 (to K. Ritthipichai and A. Aschenbrenner), RP130570 926
880 addition, the inherent properties of the less-differentiated T cells to (N. Varadarajan), RP140522 (to W.W. Overwijk), NIH grant 927
881 expressing BTLA also display enhanced resistance to apoptosis A1R03AI120027 and 1R21AI20012 (to R. Nurieva) and the Dr. Miriam and 928
882 and an efcient bioenergetic prole providing a survival advan- Sheldon G. Adelson Medical Research Foundation (AMRF), Melanoma 929
883 tage following tumor killing. These ndings support the concept Research Alliance Young Investigator Award (509800; to N. Varadarajan), 930
884 that the intrinsic attribute of the less-differentiated CD8BTLA and the Mulva Foundation. 931
The costs of publication of this article were defrayed in part by the payment of 932
885 human TIL subset together with balanced signals transduced by page charges. This article must therefore be hereby marked advertisement in 933
886 the engagement of HVEM in the tumor microenvironment on accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 934
887 melanoma cells could provide a costimulatory signal to
888 CD8BTLA TILs promoting IL2 secretion, T-cell survival, and Received May 16, 2016; revised January 29, 2017; accepted July 19, 2017; 935
889 antitumor function. published OnlineFirst xx xx, xxxx. 936
937Q9 References
938 1. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, expanded autologous tumor-inltrating lymphocytes in metastatic mela- 953
939 et al. Adoptive cell transfer therapy following non-myeloablative but noma patients. Clin Cancer Res 2012;18:675870. 954
940 lymphodepleting chemotherapy for the treatment of patients with refrac- 5. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. BTLA is 955
941 tory metastatic melanoma. J Clin Oncol 2005;23:234657. a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat 956
942 2. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz Immunol 2003;4:6709. 957
943 L, et al. Clinical responses in a phase II study using adoptive transfer of 6. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, et al. 958
944 short-term cultured tumor inltration lymphocytes in metastatic melano- B and T lymphocyte attenuator regulates T cell activation through 959
945 ma patients. Clin Cancer Res 2010;16:264655. interaction with herpesvirus entry mediator. Nat Immunol 2005;6: 960
946 3. Pilon-Thomas S, Kuhn L, Ellwanger S, Janssen W, Royster E, Marzban S, 908. 961
947 et al. Efcacy of adoptive cell transfer of tumor-inltrating lymphocytes 7. Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM. Character- 962
948 after lymphopenia induction for metastatic melanoma. J Immunother ization of phosphotyrosine binding motifs in the cytoplasmic domain of B 963
949 2012;35:61520. and T lymphocyte attenuator required for association with protein tyrosine 964
950 4. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, et al. phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun 2003; 965
951 Specic lymphocyte subsets predict response to adoptive cell therapy using 312:123643. 966

Ritthipichai et al.
969 8. Chemnitz JM, Lanfranco AR, Braunstein I, Riley JL. B and T lymphocyte 26. Liadi I, Singh H, Romain G, Rey-Villamizar N, Merouane A, Adolacion JR, 1028
970 attenuator-mediated signal transduction provides a potent inhibitory et al. Individual motile CD4() T cells can participate in efcient multi- 1029
971 signal to primary human CD4 T cells that can be initiated by multiple killing through conjugation to multiple tumor cells. Cancer Immunol Res 1030
972 phosphotyrosine motifs. J Immunol 2006;176:660314. 2015;3:47382. 1031
973 9. Otsuki N, Kamimura Y, Hashiguchi M, Azuma M. Expression and function 27. Romain G, Senyukov V, Rey-Villamizar N, Merouane A, Kelton W, Liadi I, 1032
974 of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells. et al. Antibody Fc engineering improves frequency and promotes kinetic 1033
975 Biochem Biophys Res Commun 2006;344:11217. boosting of serial killing mediated by NK cells. Blood 2014;124: 1034
976 10. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects 32419. 1035
977 of PD-1 on Akt and Ras pathways regulate molecular components of the 28. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, et al. 1036
978 cell cycle and inhibit T cell proliferation. Sci Signal 2012;5:ra46. Persistent antigen at vaccination sites induces tumor-specic CD8() T cell 1037
979 11. Gavrieli M, Murphy KM. Association of Grb-2 and PI3K p85 with phos- sequestration, dysfunction and deletion. Nat Med 2013;19:46572. 1038
980 photyrosile peptides derived from BTLA. Biochem Biophys Res Commun 29. Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, Birnbaum MJ, et al. 1039
981 2006;345:14405. Identication of a proline-rich Akt substrate as a 14-3-3 binding partner. 1040
982 12. Wakamatsu E, Mathis D, Benoist C. Convergent and divergent effects of J Biol Chem 2003;278:1018994. 1041
983 costimulatory molecules in conventional and regulatory CD4 T cells. 30. Krieg C, Boyman O, Fu YX, Kaye J. B and T lymphocyte attenuator regulates 1042
984 Proc Natl Acad Sci U S A 2013;110:10238. CD8 T cell-intrinsic homeostasis and memory cell generation. Nat 1043
985 13. Legat A, Speiser DE, Pircher H, Zehn D, Fuertes Marraco SA. Inhibitory Immunol 2007;8:16271. 1044
986 receptor expression depends more dominantly on differentiation and 31. Steinberg MW, Huang Y, Wang-Zhu Y, Ware CF, Cheroutre H, Kronenberg 1045
987 activation than "Exhaustion" of human CD8 T cells. Front Immunol M. BTLA interaction with HVEM expressed on CD8() T cells promotes 1046
988 2013;4:455. survival and memory generation in response to a bacterial infection. PLoS 1047
989 14. Haymaker CL, Wu RC, Ritthipichai K, Bernatchez C, Forget MA, Chen JQ, One 2013;8:e77992. 1048
990 et al. BTLA marks a less-differentiated tumor-inltrating lymphocyte subset 32. Forget MA, Haymaker C, Dennison JB, Toth C, Maiti S, Fulbright OJ, et al. 1049
991 in melanoma with enhanced survival properties. Oncoimmunology The benecial effects of a gas-permeable ask for expansion of Tumor- 1050
992 2015;4:e1014246. Inltrating lymphocytes as reected in their mitochondrial function and 1051
993 15. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human respiration capacity. Oncoimmunology 2015;5:e1057386. Q10 1052
994 memory T cell subset with stem cell-like properties. Nat Med 2011; 33. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, et al. 1053
995 17:12907. Mitochondrial respiratory capacity is a critical regulator of CD8 T cell 1054
996 16. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraft- memory development. Immunity 2012;36:6878. 1055
997 ment of human central memory-derived effector CD8 T cells in immu- 34. Dimeloe S, Mehling M, Frick C, Loeliger J, Bantug GR, Sauder U, et al. The 1056
998 nodecient mice. Blood 2011;117:188898. immune-metabolic basis of effector memory CD4 T cell function under 1057
999 17. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. hypoxic conditions. J Immunol 2016;196:10614. 1058
1000 Adoptive transfer of effector CD8 T cells derived from central memory 35. Jackman JK, Motto DG, Sun Q, Tanemoto M, Turck CW, Peltz GA, et al. 1059
1001 cells establishes persistent T cell memory in primates. J Clin Invest Molecular cloning of SLP-76, a 76-kDa tyrosine phosphoprotein associated 1060
1002 2008;118:294305. with Grb2 in T cells. J Biol Chem 1995;270:702932. 1061
1003 18. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, et al. 36. Harada Y, Ohgai D, Watanabe R, Okano K, Koiwai O, Tanabe K, et al. A 1062
1004 Human effector CD8 T cells derived from naive rather than memory single amino acid alteration in cytoplasmic domain determines IL-2 1063
1005 subsets possess superior traits for adoptive immunotherapy. Blood promoter activation by ligation of CD28 but not inducible costimulator 1064
1006 2011;117:80814. (ICOS). J Exp Med 2003;197:25762. 1065
1007 19. Wu J, Motto DG, Koretzky GA, Weiss A. Vav and SLP-76 interact and 37. Feau S, Arens R, Togher S, Schoenberger SP. Autocrine IL-2 is required for 1066
1008 functionally cooperate in IL-2 gene activation. Immunity 1996;4:593602. secondary population expansion of CD8() memory T cells. Nat Immunol 1067
1009 20. Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. MART-1-specic 2011;12:90813. 1068
1010 melanoma tumor-inltrating lymphocytes maintaining CD28 expression 38. Cheung TC, Steinberg MW, Oborne LM, Macauley MG, Fukuyama S, Sanjo 1069
1011 have improved survival and expansion capability following antigenic H, et al. Unconventional ligand activation of herpesvirus entry mediator 1070
1012 restimulation in vitro. J Immunol 2010;184:45265. signals cell survival. Proc Natl Acad Sci U S A 2009;106:62449. 1071
1013 21. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, et al. 39. Soroosh P, Doherty TA, So T, Mehta AK, Khorram N, Norris PS, et al. 1072
1014 Proteomic proling identies pathways dysregulated in non-small cell Herpesvirus entry mediator (TNFRSF14) regulates the persistence of T 1073
1015 lung cancer and an inverse association of AMPK and adhesion pathways helper memory cell populations. J Exp Med 2011;208:797809. 1074
1016 with recurrence. J Thorac Oncol 2010;5:1894904. 40. Gertner-Dardenne J, Fauriat C, Orlanducci F, Thibult ML, Pastor S, Fitz- 1075
1017 22. Smyth GK. Linear models and empirical bayes methods for assessing gibbon J, et al. The co-receptor BTLA negatively regulates human Vgam- 1076
1018 differential expression in microarray experiments. Stat Appl Genet Mol ma9Vdelta2 T-cell proliferation: a potential way of immune escape for 1077
1019 Biol 2004;3:Article3. lymphoma cells. Blood 2013;122:92231. 1078
1020 23. Liadi I, Roszik J, Romain G, Cooper LJ, Varadarajan N. Quantitative high- 41. Krieg C, Han P, Stone R, Goularte OD, Kaye J. Functional analysis of B and T 1079
1021 throughput single-cell cytotoxicity assay for T cells. J Vis Exp 2013:e50058. lymphocyte attenuator engagement on CD4 and CD8 T cells. J Immu- 1080
1022 24. Cancer Genome Atlas Network. Genomic classication of cutaneous nol 2005;175:64207. 1081
1023 melanoma. Cell 2015;161:168196. 42. Levy-Apter E, Finkelshtein E, Vemulapalli V, Li SS, Bedford MT, Elson A. 1082
1024 25. Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, Adaptor protein GRB2 promotes Src tyrosine kinase activation and podo- 1083
1025 et al. Memory T cell-driven differentiation of naive cells impairs adoptive somal organization by protein-tyrosine phosphatase in osteoclasts. J Biol 1084
1026 immunotherapy. J Clin Invest 2016;126:31834. Chem 2014;289:3604858. 1085

AUTHOR QUERIES
AUTHOR PLEASE ANSWER ALL QUERIES
Q1: Page: 1: AU: Per journal style, genes, alleles, loci, and oncogenes are italicized; proteins
are roman. Please check throughout to see that the words are styled correctly. AACR
journals have developed explicit instructions about reporting results from experiments
involving the use of animal models as well as the use of approved gene and protein
nomenclature at their rst mention in the manuscript. Please review the instructions at
http://aacrjournals.org/content/authors/editorial-policies#genenomen to ensure that
your article is in compliance. If your article is not in compliance, please make the
appropriate changes in your proof.
Q2: Page: 1: Author: Please verify the drug names and their dosages used in the article.
Q3: Page: 1: Author: Please verify the afliations and their corresponding author links.
Q4: Page: 1: Author: Please verify the corresponding author details.
Q5: Page: 3: Author: Please provide complete institutional details for "Dr. Roza Nurieva" and
"Dr. Willem Overwijk."
Q6: Page: 4: Author: Please conrm quality/labeling of all images included within this article.
Thank you.
Q7: Page: 13: AU:/PE: The conict-of-interest disclosure statement that appears in the proof
incorporates the information from forms completed and signed off on by each individual
author. No factual changes can be made to disclosure information at the proof stage.
However, typographical errors or misspelling of author names should be noted on the
proof and will be corrected before publication. Please note if any such errors need to be
corrected. Is the disclosure statement correct?
Q8: Page: 13: Author: The contribution(s) of each author are listed in the proof under the
heading "Authors' Contributions." These contributions are derived from forms complet-
ed and signed off on by each individual author. As the corresponding author, you are
permitted to make changes to your own contributions. However, because all authors
submit their contributions individually, you are not permitted to make changes in the
contributions listed for any other authors. If you feel strongly that an error is being made,
then you may ask the author or authors in question to contact us about making the
changes. Please note, however, that the manuscript would be held from further processing
until this issue is resolved.
Q9: Page: 13: Author/PE: Please note that the references have been renumbered in the text as
well as the list as they were cited in a random order. Please verify
Q10: Page: 14: Author: Ref. 31 has been updated as per PubMed. Please verify.
AU: Below is a summary of the name segmentation for the authors according to our records.
The First Name and the Surname data will be provided to PubMed when the article is indexed
for searching. Please check each name carefully and verify that the First Name and Surname are
correct. If a name is not segmented correctly, please write the correct First Name and Surname
on this page and return it with your proofs. If no changes are made to this list, we will assume
that the names are segmented correctly, and the names will be indexed as is by PubMed and
other indexing services.
First Name Surname
Krit Ritthipichai
Cara L. Haymaker
Melisa Martinez
Andrew Aschenbrenner
Xiaohui Yi
Minying Zhang
Charuta Kale
Luis M. Vence
Jason Roszik
Yared Hailemichael
Willem W. Overwijk
Navin Varadarajan
Roza Nurieva
Laszlo G. Radvanyi
Patrick Hwu
Chantale Bernatchez

CCR 16 1217 - LR

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

CCR 16 1217 - LR

Uploaded by

Copyright:

Available Formats

1 Cancer Therapy: Preclinical Clinical

42 Introduction unexpected nding that a population of CD8 TILs expressing a 50

Translational Relevance Materials and Methods 120

2 Clin Cancer Res; 2017 Clinical Cancer Research

www.aacrjournals.org Clin Cancer Res; 2017 3

292 Statistical analyses

335 CD8BTLATIL subset exhibits greater in vivo tumor control

4 Clin Cancer Res; 2017 Clinical Cancer Research

www.aacrjournals.org Clin Cancer Res; 2017 5

6 Clin Cancer Res; 2017 Clinical Cancer Research

www.aacrjournals.org Clin Cancer Res; 2017 7

523 tracked in peripheral blood after vaccination (Fig. 4C). On day 20

542 Dichotomous BTLA signaling: ITIM/ITSM dampens effector

8 Clin Cancer Res; 2017 Clinical Cancer Research

www.aacrjournals.org Clin Cancer Res; 2017 9

10 Clin Cancer Res; 2017 Clinical Cancer Research

www.aacrjournals.org Clin Cancer Res; 2017 11

12 Clin Cancer Res; 2017 Clinical Cancer Research

847 motif, as in the case of DITIM/ITSM, the phosphorylation of Akt

863 Our data of BTLA signaling in mouse T cells was found to be

www.aacrjournals.org Clin Cancer Res; 2017 13

14 Clin Cancer Res; 2017 Clinical Cancer Research

You might also like